CEO with 97% Voting Power Authorizes Up to 1-for-20 Reverse Split
SBFM is trading near its 52-week low of $1.01 (0.3% above the low) on light trading volume (0.2× avg).
Summary
Sunshine Biopharma's CEO, holding ~97% voting power, approved a reverse split of up to 1-for-20 at the board's discretion. The stock trades near its 52-week low at $1.01.
Key Events · Corporate Governance and Compliance · SBFM
-
Reverse Split Authorized Up to 1-for-20
CEO Dr. Steve N. Slilaty, holding ~97% voting power, approved by written consent authorizing the board to effect a reverse split of up to 1-for-20, with board discretion on whether and at what exact ratio to implement.
-
Stock Near 52-Week Low
The stock trades at $1.01, just above its 52-week low of $1.01 and far below the $24.30 high, suggesting the reverse split is likely aimed at regaining Nasdaq minimum bid compliance.
-
Board Discretion on Timing and Ratio
The board may choose any whole-number ratio up to 1-for-20 and may decide not to effect the split at all, creating uncertainty about the timing and magnitude of the share count reduction.
-
Effective 20 Days After Information Statement
The shareholder consent becomes effective 20 days after the definitive information statement is mailed to stockholders, providing a near-term window for implementation.
Analysis · SBFM · Life Sciences
The CEO, who controls approximately 97% of the voting power, has approved a reverse split of up to 1-for-20 at the board's discretion. The stock is trading at $1.01, just above its 52-week low of $1.01 and far below the $24.30 high. A reverse split is a common tool to regain Nasdaq minimum bid compliance, but it also signals distress and can accelerate selling pressure. The board now has the authority to implement the split at any ratio up to 1-for-20 without further shareholder approval, creating uncertainty about the timing and magnitude of the share count reduction.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $1.01 to $24.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.